Crescita Therapeutics Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Serge Verreault
Chief Executive Officer (CEO)
CA$462.3k
Compensación total
| Porcentaje del salario del CEO | 81.1% |
| Permanencia del CEO | 7yrs |
| Participación del CEO | 3.8% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 8.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge
Jan 04
Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?
Nov 18Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)
May 05Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 10
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | CA$462k | CA$375k | -CA$2m |
| Sep 30 2023 | n/a | n/a | -CA$658k |
| Jun 30 2023 | n/a | n/a | CA$819k |
| Mar 31 2023 | n/a | n/a | CA$1m |
| Dec 31 2022 | CA$704k | CA$375k | CA$862k |
| Sep 30 2022 | n/a | n/a | CA$627k |
| Jun 30 2022 | n/a | n/a | -CA$468k |
| Mar 31 2022 | n/a | n/a | -CA$1m |
| Dec 31 2021 | CA$651k | CA$375k | -CA$1m |
| Sep 30 2021 | n/a | n/a | -CA$3m |
| Jun 30 2021 | n/a | n/a | CA$2m |
| Mar 31 2021 | n/a | n/a | CA$95k |
| Dec 31 2020 | CA$659k | CA$338k | CA$37k |
| Sep 30 2020 | n/a | n/a | CA$146k |
| Jun 30 2020 | n/a | n/a | -CA$4m |
| Mar 31 2020 | n/a | n/a | CA$1m |
| Dec 31 2019 | CA$823k | CA$336k | CA$2m |
| Sep 30 2019 | n/a | n/a | CA$5m |
| Jun 30 2019 | n/a | n/a | CA$6m |
| Mar 31 2019 | n/a | n/a | CA$3m |
| Dec 31 2018 | CA$555k | CA$287k | CA$2m |
| Sep 30 2018 | n/a | n/a | -CA$9m |
| Jun 30 2018 | n/a | n/a | -CA$10m |
| Mar 31 2018 | n/a | n/a | -CA$9m |
| Dec 31 2017 | CA$734k | CA$173k | -CA$11m |
Compensación vs. Mercado: La compensación total de Serge($USD338.34K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD174.90K).
Compensación vs. Ingresos: La compensación de Serge ha sido consistente con los resultados de la empresa en el último año.
CEO
Serge Verreault
7yrs
Permanencia
CA$462,268
Compensación
Mr. Serge Verreault, BA, MBA has been the President of Crescita Therapeutics Inc. since April 17, 2017 and its Chief Executive Officer since April 2, 2018 and is Director from June 20, 2023. Mr. Verreault...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | CA$462.27k | 3.81% CA$ 319.0k | |
| Independent Lead Director | 8.1yrs | CA$74.75k | 0.51% CA$ 43.0k | |
| Independent Vice Chairman | 8.1yrs | CA$60.75k | 0.99% CA$ 83.2k | |
| Non-Executive Chairman | 8.1yrs | CA$72.25k | 5.43% CA$ 454.7k | |
| Independent Non-Executive Director | 2.4yrs | CA$56.75k | sin datos |
8.1yrs
Permanencia media
Junta con experiencia: La junta directiva de CTX se considera experimentada (8.1 años de antigüedad promedio).